MEDI-491 vaccine: Began Phase I trial of safety and immunogenicity in 20 healthy adult volunteers. Participants, in groups of four, will receive different doses

MedImmune Inc. (MEDI), Gaithersburg, Md.
Product: MEDI-491 vaccine
Indication:

Read the full 96 word article

How to gain access

Continue reading with a
two-week free trial.